We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Sartorius AG | TG:SRT | Tradegate | Ordinary Share |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -4.50 | -2.17% | 202.50 | 200.00 | 204.50 | 207.50 | 201.00 | 207.50 | 1,624 | 20:58:00 |
From May 2023 to May 2024
By Adria Calatayud
Sartorius said Friday that second-quarter net profit fell on sales that took a hit from weaker demand in both its bioprocess and laboratory-products divisions, and confirmed its recently downgraded outlook for 2023.
The German life-sciences group said net profit for the second quarter was 95.0 million euros ($105.7 million) compared with EUR165.8 million in the year-earlier period.
Revenue for the quarter dropped to EUR832.0 million from EUR1.04 billion a year before, with a 19% fall in bioprocess solutions and a 13% decline in lab products and services. Order intake for the quarter was down by a third at EUR684.8 million.
Sartorius's quarterly underlying earnings before interest, taxes, depreciation and amortization fell 30% to EUR244.7 million.
The company said its outlook for the year remains unchanged after it issued a profit warning last month, citing a postpandemic slump in demand.
Write to Adria Calatayud at adria.calatayud@dowjones.com
(END) Dow Jones Newswires
July 21, 2023 01:29 ET (05:29 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Sartorius Chart |
1 Month Sartorius Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
